Thai Princess Maha Chakri Sirindhorn, left, talks with Green Cross Corp. Chairman Huh Il-sup as they walk through the company's plasma derivative plant in Ochang, North Chungcheong Province, Friday. / Courtesy of Green Cross Corp.
By Kwon Ji-youn
Thai Princess Maha Chakri Sirindhorn, president of her country's Red Cross Society, visited Asia's largest plasma derivative plant in Ochang, North Chungcheong Province, Friday.
She took a first-hand look at the production process at the Green Cross Corp. factory, wrapping up a four-day trip to Korea.
Her visit is a follow-up to a $68.4 million (76 billion won) contract signed between Green Cross and the Thai Red Cross on Jan. 4, for the Korean firm to build a similar plant in Thailand by September 2015.
Construction began last month in Bang Phra, 100 kilometers south of Bangkok, and when finished it will be the largest derivative plant in Southeast Asia. It will primarily produce albumin and immunoglobin.
According to the agreement, Green Cross will also provide the Thai Red Cross with the technology and training needed to operate the facility.
Princess Sirindhorn met with Green Cross Chairman Huh Il-sup and company President Rhee Byung-geon to discuss ways of stepping up cooperation in the pharmaceutical industry between the two countries.
Thai Ambassador to Korea Kittiphong Na Ranong accompanied the princess on her visit.
The Ochang plant, built in 2009, exports products to more than 30 countries. Plasma derivatives refer to pharmaceutical products derived from human blood.
Only four Asian countries - South Korea, Japan, India and China - produce such derivatives, while others rely on imports.